PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition

Yilun Wu(Nanjing Tech University), Wenyi Gu(Qinghai University)

Frontiers in Immunology

August 27, 2019

10.3389/fimmu.2019.02022

Cited by 411

Related Papers

<scp>PI</scp>3K/Akt/<scp>mTOR</scp> pathway dual inhibitor <scp>BEZ</scp>235 suppresses the stemness of colon cancer stem cells

|Clinical and Experimental Pharmacology and Physiology|2015|98

Insluin and epithelial growth factor (EGF) promote programmed death ligand 1(PD-L1) production and transport in colon cancer stem cells

|BMC Cancer|2019|54

Synergistic inhibition of colon cancer cell growth with nanoemulsion-loaded paclitaxel and PI3K/mTOR dual inhibitor BEZ235 through apoptosis

|International Journal of Nanomedicine|2016|52

Multiple polymorphisms within the PLCE1 are associated with esophageal cancer via promoting the gene expression in a Chinese Kazakh population

|Gene|2013|43

Both treated and untreated tumors are eliminated by short hairpin RNA-based induction of target-specific immune responses

|Proceedings of the National Academy of Sciences|2009|31